Anti-Human CD20 - DyLight® 650

Leinco Technologies
Product Code: LEI-C1678
Product Group: Primary Antibodies
CodeSizePrice
LEI-C1678-50ug50 ug£159.00
Quantity:
LEI-C1678-100ug100 ug£211.00
Quantity:
LEI-C1678-200ug200 ug£291.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Mouse
Antibody Isotype: IgG2b κ
Antibody Clonality: Monoclonal
Antibody Clone: 2H7
Regulatory Status: RUO
Target Species: Human
Application: Flow Cytometry
Shipping:
2-8°C
Storage:
This DyLight® 650 conjugate is stable when stored at 2-8°C. Do not freeze.

Further Information

Antigen Distribution:
CD20 is present on human pre B lymphocytes and on B lymphocytes, except on plasma cells, and is expressed in tandem with surface IgM. It is also expressed in some follicular dendritic cells and at low levels on a T cell subset.
Concentration:
0.2 mg/ml
Conjugate/Tag/Label:
DyLight® 650
Format:
This DyLight® 650 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This DyLight® 650 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
Purified Recombinant Human CD20 (>98%)
Long Description:
CD20 is a 33-37 kD transmembrane-spanning phosphoprotein that facilitates optimal B-cell immune response against T-independent antigens. It can exist in a complex with MHC class I, MHC class II, CD53, CD81, and CD82. However, CD20 can also form homo-oligomers. It has been suggested that homo-oligomerization of CD20 forms calcium ion channels in the plasma membrane of B cells. CD20 can be useful in diagnosing B-cell lymphomas and leukemias, and is the target of mAbs in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases. Interestingly, studies show a link between the immune system's B cells and diabetes mellitus in which anti-CD20 antibodies rendered the T cell antibodies dysfunctional and, hence, unable to cause insulin desensitivity by a B cell antibody-modulated autoimmune response.
NCBI Gene:
931
Target:
CD20

References

1. Stashenko, P. et al. (1980) J. Immunol. 125:1678 2. Fang, D. et al. (2005) Cancer Res. 65:9328 3. Bubien, J. K. et al. (1993) J. Cell Biol. 121:1121 4. White, M. W. et al. (1991) J. Immunol. 146:846 5. Cragg, M. S. et al. (2005) Curr. Dir. Autoimmun. 8:140

Related Products

Product NameProduct CodeSupplier 
Anti-Human CD20 - Purified in vivo PLATINUM™ Functional GradeLEI-C1651Leinco Technologies Summary Details
Anti-Human CD20 - DyLight® 755LEI-C1680Leinco Technologies Summary Details
Anti-Human CD20 - PerCPLEI-C1682Leinco Technologies Summary Details
Anti-Human CD20 - PELEI-C1895Leinco Technologies Summary Details
Anti-Human CD20 - APCLEI-C1896Leinco Technologies Summary Details